EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma.

Status Withdrawn

Clinical Trial Summary

This study will assess if endoscopic ultrasound radiofrequency application in patients with inoperable pancreatic cancer and chemotherapy confers survival benefit when compared to patients receiving best medical care and chemotherapy .

Clinical Trial Description

Prospective randomised clinical study in patients with adenocarcinoma of the pancreas.

Patients will be randomised 1:1. Patients in the treatment group will receive standard chemotherapy plus 3 radiofrequency ablation procedures, each one month apart.

Patients in the control group will receive standard chemotherapy and best medical care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03065985
Study type	Interventional
Source	Centre hospitalier de l'Université de Montréal (CHUM)
Contact
Status	Withdrawn
Phase	Phase 2
Start date	August 2017
Completion date	March 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01064622` - Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT00375310` - Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer	Phase 1
Completed	`NCT00095966` - Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	Phase 2
Completed	`NCT00020345` - Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas	Phase 2
Completed	`NCT03871959` - Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma	Phase 1
Completed	`NCT03717298` - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma	Phase 2
Completed	`NCT01447732` - Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors	Phase 1
Withdrawn	`NCT01401387` - Pancreatic Enzyme Suppletion in Pancreatic Cancer	Phase 4
Completed	`NCT01232829` - Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer	Phase 2
Terminated	`NCT01233505` - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00735917` - Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer	Phase 2
Recruiting	`NCT04543071` - Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma	Phase 2
Terminated	`NCT03490760` - Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas	Phase 2
Completed	`NCT01068327` - Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer	Phase 1
Recruiting	`NCT05419479` - Switch Maintenance in Pancreatic	Phase 1/Phase 2
Completed	`NCT01222689` - Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	Phase 2
Completed	`NCT00028496` - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer	Phase 1
Completed	`NCT00026104` - Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer	Phase 2
Terminated	`NCT01318642` - Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas	Phase 2
Completed	`NCT00474812` - Dasatinib in Treating Patients With Metastatic Pancreatic Cancer	Phase 2